BeiGene’s Brukinsa Receives NMPA Approval for Expanded Use in Leukemia and Lymphoma
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it has received approval...
Shanghai Junshi Biosciences’ Tuoyi Shows Promise in Phase III Study for ES-SCLC
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced encouraging results from the...
Tianjin, Shandong, and Hainan Provinces Announce VBP Backup Suppliers for Round 8
Tianjin, Shandong, and Hainan provinces in China have released their lists of backup suppliers following...
Suzhou GenAssist’s GEN6050 Receives US FDA Pre-IND Acceptance for Duchenne Muscular Dystrophy Treatment
China-based Suzhou GenAssist Therapeutic Co., Ltd has announced that the US Food and Drug Administration...
Sinopharm Partners with Fudan University to Establish National Innovation Platform
China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Fudan...
Reistone Biopharma’s Edralbrutinib Earns Orphan Drug Designation for NMOSD from US FDA
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Medicine with an investment of USD...
Lingyi Biotechnology Secures RMB 100 Million in Series A Funding for Gene Therapy Pipeline
China-based gene therapy developer Lingyi Biotechnology Co., Ltd has reportedly raised close to RMB 100...
Henlius Biotech’s HLX26 and HaiSiZhuang Combo for NSCLC Gets NMPA Phase II Approval
Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the National...
Shanghai Junshi Biosciences Inks Exclusive License Deal with Dr. Reddy’s Laboratories for Tuoyi
Shanghai Junshi Biosciences Co., Ltd (SHA: 688180), a China-based biotechnology firm, has announced an exclusive...
Sinopharm Partners with Shenzhen to Boost High-End Medical Device and Pharmaceutical Innovation
China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Shenzhen...
XtalPi Inc. and China Pharmaceutical University Launch Joint AI Research Center in China
Sino-US artificial intelligence (AI) firm XtalPi Inc. has joined forces with China Pharmaceutical University (CPU)...
Omega Medical Imaging’s Soteria.AI Receives FDA Approval for Interventional Cardiology
US-based medical technology firm Omega Medical Imaging has received marketing approval from the US Food...
NMPA Extends Public Feedback Period for ‘Drug Standardization Management Measures’ in China
The National Medical Products Administration (NMPA) in China has announced an extension to the public...
Hasten Biopharm Acquires Commercial Rights to Rocephin in China from Roche
China-based Hasten Biopharmaceutical Co., Ltd has announced the acquisition of the commercial rights in China...
Mindray Reports Strong YOY Growth in 2022 and Q1 2023 Financial Results
China-based medical device firm Mindray (SHE: 300760) has released its financial reports for the year...
Anhui and Qinghai Provinces Update BMI Chronic Disease Drug Lists for Outpatient Reimbursement
The healthcare security bureaus of Anhui and Qinghai provinces in China have separately released notifications...
Huadong Medicine’s Mefatinib Poised for Breakthrough Therapy Designation by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Huadong Medicine Co., Ltd (SHE:...
VivaVision Biotech Secures Over RMB 100 Million in Series D2 Financing for Ophthalmology Pipeline Expansion
China’s VivaVision Biotech Inc. has announced the successful completion of its Series D2 financing round,...
Yantai Dongcheng Pharma’s 177Lu-LNC1003 Cleared for US FDA Phase I Study
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that it has received...
ABM Therapeutics’ ABM-168 Begins Phase I Dosing in the US for Advanced Solid Tumors
Shanghai-based ABM Therapeutics, Inc. has announced the commencement of the first patient enrollment and dosing...